Theriva Biologics (NYSE American: TOVX) announced that results from its VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE